In April 2022, Medanex announced its acquisition by NAMSA, a leading MedTech-focused Contract Research Organization (CRO) providing full continuum development solutions. Founded in 1967, NAMSA is the pioneer of the medical device testing industry and has expanded over the years to offer full development lifecycle solutions to Sponsors worldwide. These services include laboratory and preclinical testing; quality, reimbursement and regulatory consulting; clinical research solutions; IVD services and more.
Medanex, now part of NAMSA, looks forward to continuing to offer Clients the most proven, trusted preclinical research solutions in the MedTech industry. Medanex Clients will also benefit from the breadth and depth of NAMSA’s full medical device development service offerings, including:
Clinical Research Services
Biological Safety Consulting
Medical Device Testing
MRO Program: Full Development Lifecycle Resource
Product Development Strategy
Quality and Regulatory Consulting
Stay Informed on the Latest Industry Updates: NAMSA is proud to offer Clients a full suite of complimentary resources, providing critical information gained throughout NAMSA’s 55+ year history of effectively managing innovative development programs for global Sponsors. Access these to learn best practices and proven strategies critical to successful market introduction and commercialization. To be informed of important industry updates, resources and events, we invite you to sign up for NAMSA’s Newsletter, here.